AI assistant
IONIS PHARMACEUTICALS INC — Director's Dealing 2015
Jan 5, 2015
30591_dirs_2015-01-05_5433d59e-e49f-4a48-a3b5-bf375c65a92e.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: ISIS PHARMACEUTICALS INC (ISIS)
CIK: 0000874015
Period of Report: 2015-01-01
Reporting Person: BENNETT C FRANK (SVP, Antisense Research)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2015-01-01 | Common Stock | J | 136 | $30.0475 | Acquired | 4763 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2015-01-02 | Employee Stock Option (right to buy) | $61.57 | A | 31457 | Acquired | 2022-01-01 | Common Stock (31457) | Direct |
Footnotes
F1: Reporting 136 shares acquired under the Isis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on January 1, 2015. These 136 shares may not be sold until July 2, 2015.
F2: Grant of 1/2/2015 to reporting person of stock options under the Isis Pharmacueticals, Inc. 2011 Equity Incentive Plan. 25% of the shares subject to the option vest and become exercisable on 1/2/2016. Thereafter, the remaining shares subject to the option vest and become exercisable in 36 equal monthly installments, at the rate of 7,865 shares per year.The option was exercisable as to 0 on 1/2/2015.